Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAT-205 in Mild COVID-19
NCT04708327Phase 1Unknown
- Sponsor
- Statera BioPharma
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing STAT-205 with Placebo (2 arms). Primary endpoint: Proportion of patients who demonstrate progression of COVID-19 disease at Day 30. Status: unknown.
02
Drugs
STAT-205
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04708327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708327.